Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.6364.

BCAX has been the subject of a number of research reports. The Goldman Sachs Group increased their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. BMO Capital Markets started coverage on shares of Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Thursday. Finally, Wells Fargo & Company increased their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 28,214 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares in the company, valued at approximately $5,279,489.46. This trade represents a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,133,012.96. This represents a 2.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 125,500 shares of company stock valued at $3,479,986. 13.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new position in shares of Bicara Therapeutics in the 1st quarter worth approximately $248,000. Woodline Partners LP raised its holdings in Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after buying an additional 72,998 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Bicara Therapeutics by 36.8% during the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after buying an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Bicara Therapeutics by 26.0% during the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after acquiring an additional 5,664 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter.

Bicara Therapeutics Stock Performance

BCAX stock opened at $22.81 on Friday. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -7.36 and a beta of -0.82. Bicara Therapeutics has a fifty-two week low of $10.30 and a fifty-two week high of $30.99. The stock has a fifty day moving average of $25.89 and a 200-day moving average of $22.98.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). Equities analysts predict that Bicara Therapeutics will post -3.51 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.